From: Identification and characterization of lncRNA AP000253 in occult hepatitis B virus infection
 | Discovery phase | Validation phase | ||||||
---|---|---|---|---|---|---|---|---|
HCs (n = 10) | OBI (n = 10) | P | HCs (n = 20) | OBI (n = 64)a | ASC (n = 20) | CHB (n = 31)b | P | |
Demographic characteristics | ||||||||
 Female (n, %) | 1 (10.00) | 2 (20.00) | 0.53 | 6 (30.00) | 22 (34.38) | 7 (35.00) | 10 (41.94) | 0.98 |
 Age (years) | 39.30 ± 11.68 | 42.80 ± 7.96 | 0.45 | 38.00 ± 7.94 | 42.86 ± 8.81 | 36.00 ± 7.48 | 43.11 ± 14.16 | 0.09 |
Serological characteristics | ||||||||
 ALT (U/L) | 19.56 ± 7.63 | 22.70.67 ± 11.14 | 0.48 | 16.74 ± 6.41 | 18.99 ± 9.79 | 37.80 ± 8.23 | 219.94 ± 263.70 | 0.13 |
 HBsAg (S/CO, positive) | 0.31 ± 0.30 0 | 0.12 ± 0.16 0 | 0.12 | 0.21 ± 0.25 0 | 0.16 ± 0.21 0 | 22.89 ± 9.91 20 | 272.28 ± 139.62 31 | < 0.01c |
 Anti-HBs (S/CO, positive) | 7.00 ± 8.32 5 | 0.87 ± 0.72 3 | 0.04 | 8.24 ± 8.18 12 | 0.77 ± 1.21 7 | 0.21 ± 0.24 0 | 0.23 ± 0.72 0 | < 0.01c |
 HBeAg (S/CO, positive) | 0.08 ± 0.03 0 | 0.07 ± 0.02 0 | 0.89 | 0.07 ± 0.01 0 | 0.05 ± 0.02 0 | 0.06 ± 0.01 0 | 38.91 ± 82.97 7 | 0.46c |
 Anti-HBe (S/CO, positive) | 1.60 ± 0.31 0 | 1.28 ± 0.47 2 | 0.11 | 1.88 ± 0.12 0 | 0.97 ± 0.40 8 | 0.24 ± 0.34 19 | 8.53 ± 30.90 24 | < 0.01c |
 Anti-HBc (S/CO, positive) | 1.48 ± 0.47 1 | 0.71 ± 0.73 7 | 0.02 | 1.96 ± 0.40 0 | 0.45 ± 0.53 28 | 0.08 ± 0.07 20 | 11.03 ± 1.84 31 | < 0.01c |
 HBV-DNA (Ct) | NA | 34.89 ± 1.25 | NA | NA | 35.86 ± 1.87 | 33.67 ± 3.01 | 23 ~ 2.88E + 8 | < 0.01c |